The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

Paul Di Cesare,MD114 enrolled

Overview

The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

114

Conditions

Total Knee Replacement

Interventions

Fondaparinux Sodium (Arixtra)DRUG

2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All primary unilateral TKA and THA cases will be included. Exclusion Criteria: * Patients less than 50 kg, Patients with CrCl\<30ml/min. Revision and bilateral procedures will be excluded.

Locations (1)

U C Davis

Sacramento, California, United States

Outcomes

Primary Outcomes

Number of Days Until a Dry Wound

Days from day of surgery to stoppage of leakage from the wound

Time frame: Up to 10 days

Secondary Outcomes

Number of Days in Hospital.

Days after surgery to dischage

Time frame: Up to 10 days

Incidence of Wound Infection

Incidence of Cellulitis in patients undergoing Arixtra treatment

Time frame: Up to 10 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.